NEW YORK – After following PD-L1 expressing non-small cell lung cancer patients on pembrolizumab (Merck's Keytruda) for an average of three years, investigators confirmed the survival benefit it provides over chemotherapy docetaxel, as well as the effectiveness of PD-L1 as a biomarker for predicting response to the checkpoint inhibitor.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.